Unicycive Therapeutics, Inc

Alumis provides precision medicines. They transform the lives of patients with autoimmune diseases. They bring a proven track record in precision drug development of groundbreaking therapies. They rewrite the autoimmune treatment playbook with a unique precision analytics platform to advancing their understanding of immunologic diseases. They build a pipeline of therapeutics based on genetically validated targets for application in the treatment of multiple autoimmune disease indications.

Aimmune Therapeutics is a biopharmaceutical company based in Brisbane, CA, that is dedicated to developing innovative medicines for the treatment, prevention, and management of food, gastrointestinal (GI), and metabolic-related diseases. As a Nestlé Health Science company, Aimmune aims to be a global leader in this field, providing standardized, science-driven treatments for patients and their families who have limited or no other options. With a focus on reducing the burden of serious and potentially life-threatening conditions, Aimmune pushes the boundaries of medicine to enable individuals to live life on their own terms. By uniting the best minds in clinical research and biotechnology, the company is actively working on its pipeline of therapies to address these diseases and improve the lives of patients and caregivers.Generated from the website

Napo Pharmaceuticals, Inc. is a San Francisco-based company dedicated to developing and commercializing prescription medicines that provide essential supportive care for individuals undergoing treatment for diseases like cancer. Their mission is to improve the comfort, quality of life, and dignity of patients experiencing treatment-related gastrointestinal distress, particularly overactive bowel symptoms such as chronic diarrhea, urgency, and incontinence. Napo Pharmaceuticals is currently focused on their Phase 3 pivotal OnTarget trial of Mytesi crofelemer, a preventative treatment for chemotherapy-induced overactive bowel, with comprehensive results expected in Q1 2024. They also support investigator-initiated studies exploring the potential of crofelemer for rare disease indications like short bowel syndrome and microvillus inclusion disease. Napo Pharmaceuticals takes pride in their responsible harvesting practices, sourcing their medicines from plants in rainforest regions. Their prescription medicines work through a novel mechanism of action, inhibitory modulation of two secretory chloride ion channels in the gastrointestinal tract. The company is committed to uncovering medical solutions to serve those in need, advancing their understanding through high-quality research conducted by external investigators. Environmental sustainability and social responsibility are paramount to Napo Pharmaceuticals, as they prioritize the responsible harvesting of their products and share benefits with the local communities that contribute to their mission.Generated from the website